RC
RA Capital Management
Venture CapitalActiveRA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
145
Investments
10
Exits
$10B
AUM
6.9%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for RA Capital Management.
Investment Thesis & Strategy
RA Capital Management invests in life sciences and drug development companies across various stages, seeking to support innovation in the healthcare sector.
Investment Activity
Deals per year over the last 11 years
1
20100
20111
20120
20132
20142
20151
20161
20171
20182
20191
2020Portfolio Companies
Selected investments from their portfolio of 145 companies
A
Acumen Pharmaceuticals
Biotech · Series A, 2020
X
Xilio Therapeutics
Biotech · Series A, 2019
V
Verve Therapeutics
Biotech · Series A, 2019
R
Relay Therapeutics
Biotech · Series A, 2018
O
Obsidian Therapeutics
Biotech · Series A, 2017
M
Myovant Sciences
Biotech · Series A, 2016
R
Revolution Medicines
Biotech · Series A, 2015
V
Voyager Therapeutics
Biotech · Series A, 2015
I
Intellia Therapeutics
Biotech · Series A, 2014
C
CRISPR Therapeutics
Biotech · Series A, 2014
B
Blueprint Medicines
Biotech · Series A, 2012
S
Sutro Biopharma
Biotech · Growth, 2010
Notable Exits
CompanyTypeYearValue / Acquirer
Obsidian TherapeuticsAcquisition2024—
Casma TherapeuticsAcquisition2023$415M
AcelyrinIPO2023$540M
Turning Point TherapeuticsAcquisition2022$4.1B
Inari MedicalIPO2020$1.5B
Revolution MedicinesIPO2020$2.2B
BridgeBio PharmaIPO2019$3.4B
Gossamer BioIPO2019$315M
Voyager TherapeuticsIPO2017$660M
Kura OncologyIPO2014$100M
Frequently Asked Questions
RA Capital Management focuses on Series A, Series B, Series C+ stage investments.